Latest Oncology News

Avapritinib Yields Improvements in Bone Density in Advanced Systemic Mastocytosis

Avapritinib Yields Improvements in Bone Density in Advanced Systemic Mastocytosis

January 17th 2025

Courtney Flaherty

Treatment with avapritinib was associated with dynamic changes in bone density based on lumbar T-scores among patients with systemic mastocytosis.

Fox Chase Cancer Center Welcomes Dr. Qing Chen

Fox Chase Cancer Center Welcomes Dr. Qing Chen

January 17th 2025

Fox Chase Cancer Center

Qing Chen, MD, PhD, has joined as a new assistant professor in the Cancer Signaling and Microenvironment Research Program.

FDA Approves Datopotamab Deruxtecan for Unresectable or Metastatic HR+/HER2-Negative Breast Cancer

FDA Approves Datopotamab Deruxtecan for Unresectable or Metastatic HR+/HER2-Negative Breast Cancer

January 17th 2025

Chris Ryan

The FDA approved datopotamab deruxtecan for select unresectable or metastatic, hormone receptor–positive, HER2-negative breast cancer.

Senaparib Receives NMPA Approval As First-Line Maintenance in Ovarian Cancer

Senaparib Receives NMPA Approval As First-Line Maintenance in Ovarian Cancer

January 17th 2025

Courtney Flaherty

Senaparib has received marketing authorization in China as a first-line maintenance therapy for advanced ovarian cancer.

FDA Approves Companion Diagnostic for Tovorafenib in BRAF-Altered Pediatric Low-Grade Glioma

FDA Approves Companion Diagnostic for Tovorafenib in BRAF-Altered Pediatric Low-Grade Glioma

January 17th 2025

Ashling Wahner

Tovorafenib generated durable drug holiday responses in pediatric patients with BRAF-altered relapsed/refractory low-grade glioma.

Latest Oncology Videos

Dr Kalinka on Frontline BMS-986012 Plus Nivolumab and Chemotherapy in ES-SCLC
Interferon Therapy in PV
Dr Werutsky on the Effects of HER2-Low Breast Cancer Subtype on Treatment Outcomes
MDS Treatment Strategies: From Risk Assessment to Transplantation
DIssecting the Current Treatment Landscape for R/R Follicular Lymphoma
Dr Garje on Unmet Needs in Small Cell Bladder Cancer
Dr Parikh on the Clinical Implications of Molecular Testing on mCRC Management
Dr Phillips on the Rationale of Evaluating Glofitamab in R/R Mantle Cell Lymphoma
Dr Baljevic on Selinexor Plus Pomalidomide/Dexamethasone in R/R Myeloma
Dr Al Malki on the Potential Use of TSC-100 and TSC-101 After Transplant in AML, ALL, and MDS
JAK Inhibition in Polycythemia Vera: Treatment Updates
Dr Badami on the Optimal Selection of Second-Line TKIs in ccRCC
When to Choose Narrow Panel Testing Over Comprehensive Testing in Biomarker Analysis
The Importance of Broad Biomarker Testing: Uncovering Actionable Targets Across Tumor Types
Dr Philip on Considerations for Selecting First-Line Treatment in Newly Diagnosed, Low-Risk GI NETs
Dr Nathanson on BRCA1/2 Reversion Mutations in Response to Therapy in Breast Cancer
Dr Barata on Improved Clinical Outcomes with Darolutamide in mHSPC
Dr Hunter on the Development of Targeted Approaches Beyond JAK Inhibition in Myelofibrosis
Dr Westbrook on Clinical Trials That Have Shaped the Non-ccRCC Treatment Paradigm
Dr Lee on the Efficacy of Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer
Dr Kim on The Efficacy and Safety of Odronextamab in R/R MZL
Dr Goldsberry on the Risk of Secondary Malignancies With PARP Inhibitors in Ovarian Cancer
Shifting Paradigms: Biomarker Testing and ESR1 Mutation Surveillance in HR+ HER2- Breast Cancer

All Oncology News

Limertinib Wins Approval in China for EGFR T790M+ NSCLC

January 17th 2025

Chris Ryan

Limertinib was approved in China for locally advanced or metastatic non–small cell lung cancer harboring an EGFR T790M mutation.

Preliminary Efficacy, Safety Data Drive Further Exploration of Mezigdomide-Based Combinations in R/R Myeloma

January 17th 2025

Courtney Flaherty

David S. Siegel, MD, PhD, discusses early safety and efficacy data that support further development of mezigdomide-based combinations in multiple myeloma.

LOAd703 Oncolytic Adenovirus Receives FDA Fast Track Designation for Pancreatic Cancer

January 17th 2025

Ashling Wahner

LOAd703 has been granted FDA fast track designation for the treatment of patients with pancreatic cancer.

Zanidatamab Plus Evorpacept Shows Early Activity, Tolerability in Pretreated HER2+ Breast Cancer

January 17th 2025

Courtney Flaherty

Alberto Montero, MD, MBA, CPHQ, discusses early signals of efficacy and safety with zanidatamab plus evorpacept in HER2-positive and -low breast cancer.

FDA Approves Sotorasib Plus Panitumumab for KRAS G12C–Mutated Colorectal Cancer

January 16th 2025

Kristi Rosa

The FDA approved sotorasib plus panitumumab for adult select patients with KRAS G12C–mutated metastatic colorectal cancer.

FDA Approves Acalabrutinib Plus Bendamustine and Rituximab for Previously Untreated MCL

January 16th 2025

Ashling Wahner

The FDA has approved acalabrutinib plus bendamustine and rituximab for adult patients with previously untreated MCL who are ineligible for autologous HSCT.

Early Diagnosis and Treatment Are Critical in Achieving the Best Outcomes in Sarcoma

January 16th 2025

Kyle Doherty

Breelyn Wilky, MD, discusses the importance of disease screening and early diagnosis in the treatment of patients with sarcoma.

Obe-Cel Produces Durable Remissions in Adult R/R B-ALL

January 16th 2025

Chris Ryan

Obe-cel generated durable remissions in patients with relapsed/refractory B-cell acute lymphoblastic leukemia treated during the FELIX trial.

Lete-Cel Receives FDA Breakthrough Therapy Designation for Advanced Myxoid/Round Cell Liposarcoma

January 16th 2025

Ashley Chan

The FDA granted breakthrough therapy designation to lete-cel for patients with unresectable or metastatic myxoid/round cell liposarcoma.

Dana-Farber and Gustave Roussy Announce 2025 Transatlantic Exchange Scientific Program to Focus on Radioligand Therapy

January 16th 2025

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute and Gustave Roussy have announced that the topic of the Fourth Transatlantic Exchange in Oncology Conference will be “Radiopharmaceutical Therapy Meets Oncology.”

Tabelecleucel BLA Receives FDA CRL in Pretreated EBV+ Post-Transplant Lymphoproliferative Disease

January 16th 2025

Kyle Doherty

The FDA issued a CRL to the BLA of tabelecleucel in EBV+ PTLD following at least 1 prior line of treatment.

EU/UK Approvals Sought for Nogapendekin Alfa Inbakicept Plus BCG in BCG-Unresponsive NMIBC With CIS

January 16th 2025

Kristi Rosa

Nogapendekin alfa inbakicept MAAs have been submitted to the EU's EMA and the UK's MHRA for BCG-unresponsive non–muscle-invasive bladder cancer.

OST-HER2 Meets Primary End Point of Phase 2b Trial in Lung-Only Metastatic Osteosarcoma

January 16th 2025

Kristi Rosa

OST-HER2 shows promise in patients with recurrent, fully resected lung-only metastatic osteosarcoma.

Addition of ASCT to Ibrutinib Plus Rituximab Does Not Confer Benefit in Lower-Risk, Younger MCL

January 16th 2025

Ashley Chan

Martin Dreyling, MD, PhD, discusses the role of ASCT with or without an ibrutinib-based regimen in younger patients with mantle cell lymphoma.

Zenocutuzumab Addresses High Unmet Need in NRG1-Positive NSCLC and Pancreatic Cancer

January 16th 2025

Megan Hollasch

Alison Schram, MD, details data from the eNRGy study that supported the FDA approval of zenocutuzumab in NRG1 fusion–positive NSCLC and pancreatic adenocarcinoma.

See All News